Albany, NY -- (SBWIRE) -- 10/10/2019 -- Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology and Market Forecast-2028

1. Mutations in either the Polycystic Kidney Disease1 (PKD1) or Polycystic Kidney Disease2 gene can cause Autosomal Dominant Polycystic Kidney Disease, PKD1 and PKD2 encode polycystin 1 and polycystin 2 and approximately 1 in 1000 people bear a mutation in either PKD1 or PKD2 genes worldwide.
2. Autosomal Dominant Polycystic Kidney Disease affects more than 600,000 Americans and 12.4 million people worldwide.
3. Autosomal Dominant Polycystic Kidney Disease prevalence is estimated to range from 1 in 400 to 1000 live births, with 5,000–6,000 new cases diagnosed each year.

(Albany, US)DelveInsight launched a new report on Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Autosomal Dominant Polycystic Kidney Disease market report covers a descriptive overview and comprehensive insight of the Autosomal Dominant Polycystic Kidney Disease epidemiology and Autosomal Dominant Polycystic Kidney Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Autosomal Dominant Polycystic Kidney Disease market report provides insights on the current and emerging therapies.
3. Autosomal Dominant Polycystic Kidney Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Autosomal Dominant Polycystic Kidney Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease market.

Request for sample pages

"Autosomal Dominant Polycystic Kidney Disease prevalence increased with age and reached a peak value of 261 per million population in the age group of 55-59 years in Japan."

There is no cure for Autosomal Dominant Polycystic Kidney Disease and it not possible to stop cysts forming in the kidneys, however, a lot of research has been done in this space to find the ways to manage the disease. Majority of Autosomal Dominant Polycystic Kidney Disease patients will eventually develop ESRD and require RRT. The progressiveness of this disease and its complications cause debilitating effects on the health of patients and impose a significant burden, both economically and on the quality of life.

Currently approved Autosomal Dominant Polycystic Kidney Disease treatment options are mainly focused to slow the progression of Autosomal Dominant Polycystic Kidney Disease with reducing the size of the cyst. The therapeutic Autosomal Dominant Polycystic Kidney Disease market size is accounted by therapies directed toward the management of kidney and non-kidney symptoms associated with the disease and it is based on prophylactic and supportive measures. Specifically, the treatment aims for blood pressure (BP) control and maximal inhibition of the renin-angiotensin-aldosterone system (RAAS) on progressive renal disease and cardiovascular manifestations. The kidney transplantation, frequent dialysis procedures along with nutritional supplements are also driving the Autosomal Dominant Polycystic Kidney Disease market. The therapeutic Autosomal Dominant Polycystic Kidney Disease market is driven by the increase in prevalent cases and is mainly driven by the patient pools of older ages.

The approval of long-awaited treatment JYNARQUE for people at risk of having fast-progressing has filled certain unmet need in the Autosomal Dominant Polycystic Kidney Disease treatment after its launch.
To summarize, the current research on understanding the molecular details and new therapeutic targets for this rare indication, further greater number of drugs receiving special designations by regulatory bodies and approval of the long-awaited medication, provides opportunities for the future Autosomal Dominant Polycystic Kidney Disease market. Increasing acquisitions and collaborations between key players, research and development, along with the emerging pipeline drugs, are expected to create a lucrative environment for the growth of Autosomal Dominant Polycystic Kidney Disease treatment market in the forecast period. All these factors are expected to lead to positive growth in the Autosomal Dominant Polycystic Kidney Disease market size during the forecast period (2019-2028).

The launch of the emerging therapies is expected to significantly impact Autosomal Dominant Polycystic Kidney Disease treatment scenario in the upcoming years:-
Drugs covered
1. Venglustat
2. Bardoxolone
3. Lixivaptan
4. RGLS4326
And many others

The key players in Autosomal Dominant Polycystic Kidney Disease market are:
1. Kyowa Hakko Kirin
2. Palladio Biosciences
3. Sanofi
4. Reata Pharmaceuticals
5. Regulus Therapeutics
And many others

Table of contents

1. Report Introduction
2. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
3. Autosomal Dominant Polycystic Kidney Disease Background and Overview
4. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
4.6. United States
4.7. EU-5
4.8. Assumptions and Rationale
4.9. Germany
4.10. France
4.11. Italy
4.12. Spain
4.13. United Kingdom
5. Autosomal Dominant Polycystic Kidney Disease Treatments & Medical Practices
6. Autosomal Dominant Polycystic Kidney Disease Marketed Therapies
6.1. Jynarque (tolvaptan): Otsuka Pharmaceuticals
7. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
8. Key Cross Competition
8.1. Venglustat: Sanofi
8.2. Lixivaptan: Palladio Biosciences
8.3. Bardoxolone: Reata Pharmaceuticals
8.4. XRx-008: XORTX Therapeutics
8.5. RGLS4326: Regulus Therapeutics
9. Autosomal Dominant Polycystic Kidney Disease Market Size
10. 7MM Autosomal Dominant Polycystic Kidney Disease Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight